A Mission for Making Good Medicine The University of Tennessee Research Foundation (UTRF), the University of Tennessee Health Science Center (UTHSC), and biotech therapeutics startup Anviron recently announced a partnership to commercialize a novel treatment with promising efficacy against pancreatic cancer tumors. According to the Genetic and Rare Diseases Information Center, the total number of (read more)
UTHSC
UTRF Licensee Announces Positive Phase 2 Clinical Results of VERU-111 for COVID-19
UTRF licensee Veru, Inc. announced today significant potential of VERU-111 in treating COVID-19, both as a broad-spectrum antiviral and an anti-inflammatory agent, which may help prevent effects leading to Acute Respiratory Distress Syndrome. Statistically significant data from the Phase 2 clinical study results show an 81% relative reduction in death or respiratory failure at Day (read more)
UTHSC Researchers Play Role in Supporting Development of COVID-19 Vaccines
To reduce the risk to workers developing and testing the COVID-19 vaccine, Pfizer-BioNTech and other companies have utilized a surrogate system, one of which was developed in the laboratory of Michael Whitt, PhD, a UTHSC virologist and UTRF innovator. Story written by Peggy Reisser, UTHSC Researchers at the University of Tennessee Health Science Center have (read more)